Authors: Benjamin Gaborit; Bernard Vanhove; Marie-Anne Vibet; Aurélie Le Thuaut; Karine Lacombe; Vincent Dubee; Florence Ader; Virginie Ferre; Eric Vicaut; Jéremie Orain; Morgane Le Bras; Anne Omnes; Laetitia Berly; Alexandra Jobert; Pascale Morineau-Le Houssine; Karine Botturi; Régis Josien; Laurent Flet; Nicolas Degauque; Sophie Brouard; Odile Duvaux; Alexandra Poinas; François Raffi; Eric Dailly; Thomas Guimard; Cécile Braudeau; Denis Malvy; Jean-François Faucher; Gabriela Illes Hajnal; Marc-Olivier Vareil; Mariam Roncato-Saberam; Laurent Vacher; Charlotte Biron; Maeva Lefebvre; Géraldine Gallot; Paul Le Turnier; Colin Deschanvres; Raphael Lecomte; Marie Chauveau; Anne-sophie Lecompte; Matthieu Grégoire; Ronan Bellouard; Guillaume Deslandes; Zineb Ouazene; Diane Bollens; Thibault Chiarabani; Jessica Krause-Le Garrec; Agathe Becker; Pierre Chauvelot; Anne Conrad; Tristan Ferry; Patrick Miailhes; Cécile Pouderoux; Sandrine Roux; Claire Triffault-Fillit

Venue: Trials

Type: Publication

Abstract: Abstract Background Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages such as providing immediate immunity, consequently blunting an early pro-inflammatory pathogenic endogenous antibody response and lack of drug-drug interactions. By providing immediate immunity and inhibiting entry into cells, neutralizing antibody treatment is of interest for patient with COVID-19-induced moderate pne... (read more)

DOI: 10.1186/s13063-021-05132-9